AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PML-RARA FLT3 NPM1 CEBPA Test sale cost 4400 AED
Grandparent DNA Test sale cost 4800 AED Grandparent DNA Test Cost 6,000 د.إ Original price was: 6,000 د.إ.4,800 د.إCurrent price is: 4,800 د.إ.
Eosinophilic Leukemia Panel FISH PDGFRA PDGFRB FGFR1C BFB Test sale cost 4870 AED Eosinophilic Leukemia Panel FISH PDGFRA PDGFRB FGFR1C BFB Test Cost 5,410 د.إ Original price was: 5,410 د.إ.4,870 د.إCurrent price is: 4,870 د.إ.
Sale!

AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PML-RARA FLT3 NPM1 CEBPA Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The “AML Prognostic Panel” is a comprehensive diagnostic test designed for patients diagnosed with Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow. This panel includes a variety of genetic tests that help in determining the prognosis of AML patients, guiding treatment decisions, and predicting treatment response. The key components of this panel are Cytogenetics and Polymerase Chain Reaction (PCR) tests targeting specific genetic markers, including AMLETO INV16, PML-RARA, FLT3, NPM1, and CEBPA.

1. **Cytogenetics** – This test looks at the chromosomes of cells from samples of peripheral blood or bone marrow to identify any genetic abnormalities that might be driving the leukemia.

2. **PCR (Polymerase Chain Reaction)** – PCR is a highly sensitive technique used to amplify and detect specific genetic mutations and rearrangements that are known to be associated with AML.

– **AMLETO INV16** (also known as CBFB-MYH11) – A specific chromosomal abnormality that can be detected in AML patients, which can influence treatment choices.
– **PML-RARA** – Associated with Acute Promyelocytic Leukemia (APL), a subtype of AML, this genetic marker is crucial for diagnosis and monitoring response to therapy.
– **FLT3** – Mutations in the FLT3 gene are common in AML and are associated with a poor prognosis. Testing for FLT3 mutations helps in risk stratification and may guide therapy choices.
– **NPM1** – Mutations in the NPM1 gene are among the most common genetic changes in AML and can have implications for prognosis and treatment.
– **CEBPA** – Mutations in the CEBPA gene are associated with a favorable prognosis in some cases of AML.

Performed at DNA Labs UAE, a leading diagnostic laboratory, the AML Prognostic Panel offers a thorough genetic analysis for AML patients. The cost of the test is 4400 AED, reflecting the comprehensive nature of the panel and the advanced technologies employed. By providing detailed genetic insights, this test plays a critical role in tailoring treatment strategies to individual patients, ultimately aiming to improve outcomes in AML management.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test

At DNA Labs UAE, we offer the AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test. This diagnostic test combines cytogenetic analysis and polymerase chain reaction (PCR) to detect specific genetic abnormalities associated with acute myeloid leukemia (AML).

Test Details

The AML Prognostic Panel includes the following genetic abnormalities:

  1. AML/ETO: This refers to the fusion of two genes, AML1 and ETO, resulting in a specific genetic abnormality (translocation t(8;21)(q22;q22)). It is associated with a favorable prognosis in AML.
  2. INV[16]: This refers to the inversion of chromosome 16, resulting in a specific genetic abnormality (inv(16)(p13q22) or t(16;16)(p13;q22)). It is associated with a favorable prognosis in AML.
  3. PML/RARA: This refers to the fusion of two genes, PML and RARA, resulting in a specific genetic abnormality (t(15;17)(q22;q12)). It is associated with acute promyelocytic leukemia (APL), a subtype of AML with a favorable prognosis.
  4. FLT3: This refers to mutations in the FLT3 gene, which is involved in cell growth and survival. FLT3 mutations are associated with a poor prognosis in AML.
  5. NPM1: This refers to mutations in the NPM1 gene, which is involved in cell growth and proliferation. NPM1 mutations are associated with a favorable prognosis in AML.
  6. CEBPA: This refers to mutations in the CEBPA gene, which is involved in the regulation of blood cell development. CEBPA mutations are associated with a favorable prognosis in AML.

By analyzing these genetic abnormalities, the AML Prognostic Panel can provide important information about the prognosis and treatment options for patients with AML.

Test Components

The test components for the AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test include:

  • EDTA Vacutainer (3 ml)

Test Cost

The cost of the AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test is AED 4400.0.

Sample Condition

The sample condition required for this test is bone marrow or peripheral blood. It is important to transport the sample immediately for accurate results.

Report Delivery

The report for the AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test will be delivered within 5-7 days.

Method

The AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test is performed using cell culture and end point PCR methods.

Test Type

The AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test falls under the genetics test category.

Doctor

This test can be ordered by a gynecologist.

Test Department

This test is conducted in the Genetics department.

Pre Test Information

The AML Prognostic Panel (Cytogenetics + PCR) (AML/ETO, INV 16, PML/RARA, FLT3, NPM1, CEBPA) can be done with a doctor’s prescription. However, the prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Name AML Prognostic Panel Cytogenetics and PCR AMLETO INV16 PMLRARA FLT3 NPM1 CEBPA Test
Components EDTA Vacutainer (3 ml)
Price 4400.0 AED
Sample Condition Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery 5-7 days
Method Cell culture+ End point PCR
Test type Genetics
Doctor Gynecologist
Test Department:
Pre Test Information AML Prognostic Panel (Cytogenetics + PCR) (AML/ETO, INV 16], PML/RARA, FLT3, NPM1, CEBPA) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The AML Prognostic Panel is a diagnostic test that combines cytogenetic analysis and polymerase chain reaction (PCR) to detect specific genetic abnormalities associated with acute myeloid leukemia (AML). The panel includes the following genetic abnormalities:

1. AML/ETO: This refers to the fusion of two genes, AML1 and ETO, resulting in a specific genetic abnormality (translocation t(8;21)(q22;q22)). It is associated with a favorable prognosis in AML.

2. INV[16]: This refers to the inversion of chromosome 16, resulting in a specific genetic abnormality (inv(16)(p13q22) or t(16;16)(p13;q22)). It is associated with a favorable prognosis in AML.

3. PML/RARA: This refers to the fusion of two genes, PML and RARA, resulting in a specific genetic abnormality (t(15;17)(q22;q12)). It is associated with acute promyelocytic leukemia (APL), a subtype of AML with a favorable prognosis.

4. FLT3: This refers to mutations in the FLT3 gene, which is involved in cell growth and survival. FLT3 mutations are associated with a poor prognosis in AML.

5. NPM1: This refers to mutations in the NPM1 gene, which is involved in cell growth and proliferation. NPM1 mutations are associated with a favorable prognosis in AML.

6. CEBPA: This refers to mutations in the CEBPA gene, which is involved in the regulation of blood cell development. CEBPA mutations are associated with a favorable prognosis in AML.

By analyzing these genetic abnormalities, the AML Prognostic Panel can provide important information about the prognosis and treatment options for patients with AML.

SKU: TEST-4588 Category:

Related products